Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation
- 17 February 2021
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (8) , 1118-1130
Abstract
Methotrexate is the gold standard treatment in rheumatoid arthritis. This article is protected by copyright. All rights reservedKeywords
Funding Information
- Universidad Autónoma de San Luis Potosí (C19‐FAI‐05‐60.60)
This publication has 34 references indexed in Scilit:
- FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemiaCancer Cell International, 2013
- Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: Effect of route of administration on variability in intracellular methotrexate polyglutamate concentrationsArthritis & Rheumatism, 2010
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- The Disease Activity Score and the EULAR Response CriteriaRheumatic Disease Clinics of North America, 2009
- Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long‐term methotrexate treatmentArthritis & Rheumatism, 2009
- Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 2008
- Epidemiology of adult rheumatoid arthritisAutoimmunity Reviews, 2005
- Plasma clearanceJournal of Veterinary Pharmacology and Therapeutics, 2004
- Kinetics of Methotrexate and Its Metabolites in Red Blood CellsCancer Drug Delivery, 1987
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981